India’s government has ordered a new pricing intervention covering 137 non-scheduled anti-cancer drug formulations, with revised maximum retail prices (MRPs) taking effect on November 9, 2026. The National Pharmaceutical Pricing Authority (NPPA), which operates under the Department of Pharmaceuticals, has capped trade margins on the identified medicines at 30% of their maximum retail price. Depending on their existing price structures, some medicines could see price reductions of up to 70%.
The measure is intended to make cancer treatment more affordable by limiting markups across the medicine distribution and retail supply chain. The covered formulations include a range of cancer treatments, including immunotherapies and targeted medicines used for different cancers. However, the announced reduction is a maximum potential cut, not a guaranteed discount for every medicine or patient. Actual savings will depend on each formulation’s revised price, the amount of medicine required and other treatment-related expenses.
Key Takeaways
- 137 formulations covered: The NPPA has introduced trade-margin controls for 137 non-scheduled anti-cancer drug formulations.
- Effective date: Revised prices take effect on November 9, 2026.
- Maximum expected reduction: Some MRPs could fall by up to 70%, depending on existing pricing structures.
- Trade-margin limit: The margin is capped at 30% of MRP under the new framework.
- Wide range of medicines: The list includes patented and non-patented treatments, subject to the notification’s conditions.
- Compliance requirements: Manufacturers must submit revised prices, while pharmacies and hospitals must display and charge the updated prices.
- Patient savings: The government has projected annual savings of around ₹2,500 crore from the broader intervention, but individual savings will vary.
What Has the Government Announced?
The NPPA notified the Trade Margin Rationalisation (TMR) measure on October 17, 2026, using its powers under Paragraph 19 of the Drugs (Prices Control) Order, 2013.
The intervention targets non-scheduled anti-cancer formulations. These medicines are not covered by the same routine ceiling-price mechanism that applies to scheduled formulations, although they remain subject to other applicable drug-pricing and regulatory rules.
Under the new order, trade margins for the identified medicines are restricted to 30% of MRP. Manufacturers must inform the NPPA of revised prices within seven days of publication of the notification. The revised prices will come into force on November 9, and retailers and hospitals must follow the updated rates from that date.
The government has also directed pharmaceutical companies to publish revised price lists on their websites and circulate them to retailers and hospitals. Hospitals are required to display updated prices, while state drug controllers will help monitor compliance.
| Policy detail | What it means |
|---|---|
| Medicines covered | 137 identified non-scheduled anti-cancer formulations |
| Regulator | National Pharmaceutical Pricing Authority |
| Trade-margin cap | 30% of MRP under the notified formula |
| Notification date | October 17, 2026 |
| Revised prices effective | November 9, 2026 |
| Expected maximum reduction | Up to 70%, depending on existing prices |
| Compliance monitoring | NPPA, state drug controllers, retailers and hospitals |
The list of covered medicines may be updated periodically, according to the government. Patients should check the specific formulation and strength rather than assume every product used in cancer treatment is covered.
Why Cancer Drug Prices Can Be So High
The price of a medicine paid by a patient can include more than the amount received by its manufacturer. Medicines may pass through stockists, distributors, pharmacies and hospitals before reaching the person who needs them.
Each part of the supply chain can add costs and margins. In some cases, the cumulative difference between the initial selling price and the final MRP can be substantial.
The government cited NPPA analysis indicating that non-scheduled anti-cancer medicines had average trade markups of around 170%, with some cases reaching 700% or more. Such markups can create a large gap between the price at which a medicine enters the distribution chain and the price charged to a patient.
The new measure is intended to address excessive margins while allowing manufacturers to receive legitimate revenue for supplying medicines. The policy is therefore focused on how prices are calculated and marked up through the supply chain, rather than imposing an identical percentage reduction on every manufacturer’s price.
Cancer treatment can involve repeated purchases or administration of costly medicines. Even a reduction in the price of one formulation may therefore make a meaningful difference for a patient who needs it regularly. The size of that benefit will depend on the treatment regimen and the revised price of the particular medicine.
Which Cancer Medicines Are Covered?
The 137 formulations include medicines used in immunotherapy and targeted cancer treatment, along with other anti-cancer medicines selected following recommendations from an expert committee under the Directorate General of Health Services.
The list includes formulations containing drugs such as:
- Pembrolizumab and nivolumab: Immunotherapy medicines used for certain cancers.
- Palbociclib and ribociclib: Targeted treatments used for specific types of breast cancer.
- Osimertinib: A targeted treatment used for certain forms of lung cancer.
- Bevacizumab: A medicine used in treating several cancers, depending on the clinical indication.
- Olaparib: A targeted treatment used for certain cancers involving specific genetic characteristics.
- Enzalutamide: A medicine used for particular forms of prostate cancer.
- Daratumumab: A treatment used for multiple myeloma.
This list provides examples of the medicines discussed in reporting on the notification; it is not a substitute for the official list of formulations, strengths and dosage forms.
The order’s scope is based on the identified formulations and applicable conditions, including the notification’s treatment of different strengths, dosage forms and routes of administration. Patients should confirm coverage using the official price list, their pharmacist or the hospital pharmacy.
The price measure also does not mean every patient with a particular type of cancer will receive the same benefit. A medicine may be suitable only for certain diagnoses or clinical circumstances, and treatment decisions must remain with the patient’s oncology team.
How Much Could Patients Save?
The government expects the intervention to reduce the MRPs of the covered medicines by as much as 70%, depending on existing price structures. The difference between the maximum reduction and the actual reduction is important when estimating a patient’s likely savings.
Consider a hypothetical medicine with a current MRP of ₹10,000. If its revised MRP falls by 20%, it would cost ₹8,000. A 50% reduction would bring the price to ₹5,000, while a 70% reduction would bring it to ₹3,000.
| Existing MRP | After a 20% cut | After a 50% cut | After a 70% cut |
|---|---|---|---|
| ₹5,000 | ₹4,000 | ₹2,500 | ₹1,500 |
| ₹10,000 | ₹8,000 | ₹5,000 | ₹3,000 |
| ₹50,000 | ₹40,000 | ₹25,000 | ₹15,000 |
| ₹1,00,000 | ₹80,000 | ₹50,000 | ₹30,000 |
These figures are illustrative calculations, not the confirmed revised prices of specific medicines.
The effect on a patient’s total treatment bill will also depend on how much medicine is needed and how often it is administered. Cancer care can include diagnostic tests, consultations, hospital stays, surgery, radiation therapy, supportive medicines and other expenses that are not automatically reduced by this order.
For this reason, patients should compare the updated MRP of their prescribed formulation rather than apply a blanket 70% reduction to their entire treatment budget.
Government Expects Lower Out-of-Pocket Costs
The government previously estimated that the wider cancer-medicine price-control intervention could generate savings of around ₹2,500 crore annually for patients. That figure is a policy estimate, not a guarantee of savings for each household.
The potential benefit is significant because many cancer treatments require prolonged care and can place heavy financial pressure on families. Medicines with high retail prices may consume a substantial portion of a household’s healthcare budget, particularly when treatment is not fully covered by insurance or public assistance.
The new measure expands on the NPPA’s 2019 Trade Margin Rationalisation exercise, which covered 42 non-scheduled anti-cancer medicines. The earlier initiative led to reductions of up to 91% in the MRPs of 526 brands, according to government reporting, and was associated with estimated annual savings of approximately ₹984 crore.
The latest intervention extends the approach to a larger set of formulations. However, the earlier experience should not be interpreted as proof that every medicine in the new list will experience the same reduction. The result depends on the original price structure and the calculation used under the current notification.
What Changes for Pharmacies, Hospitals and Drugmakers?
The order imposes responsibilities across the medicine supply chain.
Manufacturers must submit revised prices to the NPPA within the prescribed period and publish updated price lists. They must also communicate the changes to retailers and hospitals so that the new MRPs can be implemented from November 9.
Retail pharmacies must charge the revised prices and display the updated information. Hospitals and medical institutions, which receive a substantial share of anti-cancer medicines directly, are also expected to ensure that the revised prices are applied to eligible formulations.
State drug controllers will monitor compliance alongside the NPPA. The government has said manufacturers must maintain production and supply levels for the notified formulations to help avoid shortages following the price intervention.
This supply requirement matters because a lower official price is of limited benefit if patients cannot obtain the medicine they need. The policy therefore seeks to combine lower prices with continued availability.
Patients who notice a discrepancy after November 9 should first verify that the exact medicine, strength and formulation are included in the notification. They can then compare the price against the revised list and raise concerns with the pharmacy, hospital or appropriate regulatory authority.
How to Check the Revised Prices
The government has directed manufacturers to publish updated price lists on their websites and circulate them to pharmacies and hospitals. Patients can also use the NPPA website and the Pharma Sahi Daam app to check medicine prices.
When checking a price, patients should match the exact product name, strength, dosage form and pack size. Different formulations of medicines containing the same active ingredient may have different prices.
Patients should not switch brands, change doses or stop treatment simply because a different product appears cheaper. Any substitution or change in treatment should be discussed with the prescribing doctor or pharmacist to ensure that it is clinically appropriate.
The revised prices become effective on November 9, 2026. Until then, patients should check the applicable current price and confirm when the new rate becomes available for the medicine they use.
The Bigger Picture
The decision to cap trade margins on 137 anti-cancer drug formulations reflects the government’s effort to address the cost of cancer treatment by regulating markups across the supply chain. By expanding the earlier trade-margin rationalisation programme, the NPPA aims to reduce the gap between the price at which medicines enter distribution and the amount patients ultimately pay.
The real impact will depend on implementation, accurate price disclosures and continued medicine availability. A reduction of up to 70% could deliver substantial relief for some medicines, but the measure will not automatically make every cancer treatment affordable or reduce all other healthcare expenses. Patients will need clear, product-specific price information to understand the savings available to them.
Looking Ahead
The revised prices will take effect on November 9, and manufacturers, pharmacies and hospitals must prepare for the transition. Patients should look for updated price lists and use official tools to verify the price of the exact formulation they have been prescribed. Regulatory monitoring will be important to ensure that the new MRPs are followed and that lower prices do not lead to interruptions in supply.
Over time, the government will need to assess whether the intervention delivers the expected savings and whether additional medicines should be covered. The policy’s success will depend on the actual reductions patients receive, the reliability of supply and the transparency of prices throughout the healthcare system. For families managing cancer treatment, those practical outcomes will matter more than the headline maximum reduction alone.
Frequently Asked Questions
1. When will cancer drug prices be reduced in India?
The revised prices for the 137 identified anti-cancer drug formulations will take effect on November 9, 2026.
2. Will all 137 cancer drugs become 70% cheaper?
No. The government expects reductions of up to 70%, depending on the existing price structure. The actual reduction will vary by formulation.
3. Which authority is implementing the price changes?
The National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, has notified the trade-margin rationalisation measure.
4. Does the 30% cap apply to every cancer medicine in India?
No. It applies to the 137 identified non-scheduled anti-cancer formulations covered by the notification. Patients should check the official list to confirm whether a specific medicine is included.
5. How can patients check the new medicine prices?
Patients can check revised price lists published by manufacturers, the NPPA website and the government’s Pharma Sahi Daam app. They should match the exact formulation, strength and pack size.
6. Will the price cuts reduce the entire cost of cancer treatment by 70%?
No. The measure affects the prices of covered medicines, not every component of cancer care. Hospital charges, tests, consultations, surgery and other expenses may remain unchanged.
Get the day’s top stories in your inbox
One concise email. No spam, unsubscribe anytime.
